Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Doxorubicin × Plasma cell × Clear all

Phase

Phase 2 17 Phase 3 13 Phase 1 5 Phase 1/2 4 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 12 Other hematologic neoplasm 9 Breast 3 Genitourinary 2 Gastrointestinal 2 Sarcoma 1 Plasma cell 1 Other 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Lenalidomide 9 Dexamethasone 9 Bortezomib 8 Zoledronic Acid 7 Melphalan 4 ixazomib 3 daratumumab 3 Prednisone 3 Cyclophosphamide 3 tocilizumab 2 pomalidomide 2 carfilzomib 2 Thalidomide 2 Filgrastim 2 Calcium Dobesilate 2 zanubrutinib 1 talquetamab 1 pegylated granulocyte colony-stimulating factor 1 montelukast 1 isatuximab 1 ibrutinib 1 fludarabine phosphate 1 fludarabine 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 apixaban 1 Vaccination 1 Thiotepa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02577783 2020-02-05

PDD vs PAD to Treat Initially Diagnosed MM

The First Affiliated Hospital of Soochow University

Phase 4 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡